Search research articles
Contact Us
Filters
Showing results (21-30 of 126) with videos related to
Page
of 13
Sort By:
Leukemia Research
|
February 29, 2024
A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
Yulia Sidi, Cassie Dong, Yujun Wu, et al.
Anti-Cancer Drugs
|
May 6, 2008
Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity
Andrew M Rankin, Douglas V Faller, Remco A Spanjaard
Hematology/Oncology Clinics of North America
|
March 5, 2014
Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies
Susan P Perrine, Betty S Pace, Douglas V Faller
Virology
|
May 22, 2003
Mutations that abrogate transactivational activity of the feline leukemia virus long terminal repeat do not affect virus replication
Ana L Abujamra, Douglas V Faller, Sajal K Ghosh
FEBS Letters
|
November 6, 2007
Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide
Christina N Mork, Douglas V Faller, Remco A Spanjaard
Cellular Signalling
|
January 17, 2009
PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1
Shuhua Xia, Zhihong Chen, Lora W Forman, et al.
Nucleic Acid Therapeutics
|
August 27, 2013
Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells
Andrew M Rankin, Lora Forman, Sibaji Sarkar, et al.
Cellular Signalling
|
July 24, 2002
The role of Ras in T lymphocyte activation
Peihong Ma, Maureen Magut, Douglas V Faller, et al.
The Laryngoscope
|
August 2, 2002
Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells
Srinivasan Krishna, Neil Brown, Douglas V Faller, et al.
BMC Cancer
|
February 18, 2014
Protein kinase C-δ inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo
Zhihong Chen, Lora W Forman, Robert M Williams, et al.
Page
of 13
Search research articles
Search
Showing results (21-30 of 126) with videos related to
Sort By:
Page
of 13
Leukemia Research
|
February 29, 2024
A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
Yulia Sidi, Cassie Dong, Yujun Wu, et al.
Anti-Cancer Drugs
|
May 6, 2008
Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity
Andrew M Rankin, Douglas V Faller, Remco A Spanjaard
Hematology/Oncology Clinics of North America
|
March 5, 2014
Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies
Susan P Perrine, Betty S Pace, Douglas V Faller
Virology
|
May 22, 2003
Mutations that abrogate transactivational activity of the feline leukemia virus long terminal repeat do not affect virus replication
Ana L Abujamra, Douglas V Faller, Sajal K Ghosh
FEBS Letters
|
November 6, 2007
Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide
Christina N Mork, Douglas V Faller, Remco A Spanjaard
Cellular Signalling
|
January 17, 2009
PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1
Shuhua Xia, Zhihong Chen, Lora W Forman, et al.
Nucleic Acid Therapeutics
|
August 27, 2013
Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells
Andrew M Rankin, Lora Forman, Sibaji Sarkar, et al.
Cellular Signalling
|
July 24, 2002
The role of Ras in T lymphocyte activation
Peihong Ma, Maureen Magut, Douglas V Faller, et al.
The Laryngoscope
|
August 2, 2002
Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells
Srinivasan Krishna, Neil Brown, Douglas V Faller, et al.
BMC Cancer
|
February 18, 2014
Protein kinase C-δ inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo
Zhihong Chen, Lora W Forman, Robert M Williams, et al.
Page
of 13